We appreciate the comments by Settergren et al on differences in the patient population and response to lipid-lowering therapies between our 2 studies. 1, 2 We agree that our patient population had lower cardiovascular risks and higher on-treatment low-density lipoprotein cholesterol (LDL-C) levels. Thus, it is possible that LDL-C lowering alone may not be the overwhelming determinant of endothelial function as observed in our study. Furthermore, the lipid-lowering response to statin monotherapy and the combination of statin and ezetimibe may differ between white and Asian patients. 3 Regardless of these ethnic and cardiovascular risk factor differences, the LDL reduction was similar between simvastatin 40 mg and simvastatin/ezetimibe 10 mg/10 mg in our study. However, endothelial function differed significantly between these 2 treatment groups (simvastatin 40 mg versus simvastatin/ezetimibe 10/10 mg: ϩ32.1% versus Ϫ0.5%, PϽ0.01). Because of these contrasting results, we agree that there is a need for a larger-scale and perhaps multicenter study to further investigate whether changes in endothelial function with statin therapy are solely dependent on LDL-C lowering and, if so, whether they are affected by patient background and the degree of LDL-C lowering.
From the results of the Pravastatin or Atorvastatin Evaluation and Infection Therapy/Thrombolysis in Myocardial Infarction 22 (PROVE-IT/TIMI 22) and the Treating to New Targets (TNT) trials, it is clear that a greater reduction in LDL-C with either a more potent statin, a higher dose of statin, or both leads to a greater reduction in cardiovascular events. 4, 5 What is not known is whether there are any differences in cardiovascular outcomes depending on how you achieve the LDL-C goal. This will hopefully be addressed indirectly in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), 6 especially if the results turn out to be negative, because LDL-C levels will be lower in the Vytorin group. Thus, until the results of IMPROVE-IT are known, there is great interest in whether, with comparable LDL-C lowering and the absence of adverse effects, there are any potential differences between higher-dose statin monotherapy and combination therapy of lower-dose statin plus ezetimibe.
As pointed out by Westerink and Visseren, there are conflicting results from other studies with regard to statin monotherapy versus statin/ezetimibe combination therapy on endothelial function. One possibility is that some of these previous clinical studies lacked a control-placebo group to distinguish whether changes in flowmediated dilation (FMD) could have occurred by chance. Without a comparable placebo group, it is not possible to definitively conclude that the reduction in LDL-C and improvement in FMD are causal. Furthermore, our findings are in agreement with the results of other studies showing that ezetimibe, either alone or in combination with statins, is less effective in improving endothelial function than statin monotherapy. 7, 8 Indeed, we recently showed that inhibition of Rho-kinase (ROCK) leads to improvement in endothelial function 9 and atorvastatin 80 mg inhibited ROCK activity more than atorvastatin 10 mg. 10 As far as we know, ezetimibe alone does not reduce ROCK activity but may actually increase ROCK activity through a reciprocal increase in 3-hydroxy-3-methyl-glutaryl-CoA reductase and RhoA/ROCK activities resulting from a decrease in intestinal cholesterol absorption. Similarly, higher-dose or more potent statins have greater effects on lowering high-sensitivity C-reactive protein levels compared with lower dose or less potent statins. 11 Perhaps the reduction in ROCK activity and high-sensitivity C-reactive protein levels could be regarded as cholesterol-independent or "pleiotropic" effects of statins. Thus, although definitive clinical results are not yet known, in the absence of side effects, it is probably more prudent to give higher-dose or more potent statin monotherapy to achieve LDL-C goals in order to maximize potential cholesterol-dependent and cholesterol-independent beneficial effects of statins. The effects of statins on endothelial function are likely dependent on both of these mechanisms.
With regard to the comments by Tershakovec et al on FMD and LDL-C values in our article, we recently showed that FMD values are lower among heavy smokers compared with age-and sexmatched healthy Asian volunteers (smokers versus healthy subjects: 6.3Ϯ1.8% versus 10.2Ϯ2.5%, PϽ0.05). 12 Thus, we agree that the subjects in our study whose baseline FMD values are 6.4% to 7.8% are somewhat lower than healthy subjects. However, the baseline FMD values were not significantly different between the treatment groups (simvastatin 40 mg versus simvastatin/ezetimibe 10/10 mg: 6.39Ϯ2.3% versus 7.85Ϯ2.6, PϾ0.05). These results were obtained by 2 independent investigators who were blinded to the treatment aims. The intra-and interobserver variability were 0.9% and 1.4%, respectively. 12, 13 Although the sample size of our study was relatively small, the reproducibility was quite high. In terms of LDL-C changes in our study, the lipid-lowering response to statin monotherapy and a combination of statin and ezetimibe may differ between white and Asian patients. 3 However, regardless of these ethnic and background differences, the baseline LDL-C and the LDL-C reduction were similar between simvastatin 40 mg and simvastatin/ezetimibe 10 mg/10 mg in our study (simvastatin 40 mg versus simvastatin/ezetimibe 10/10 mg: Ϫ38.5% versus Ϫ34.8%, PϾ0.05). Despite comparable LDL-C reduction, endothelial function differed significantly between these 2 treatment groups (simvastatin 40 mg versus simvastatin/ezetimibe 10/10 mg: ϩ32.1% versus Ϫ0.5%, PϽ0.01). These findings are in agreement with the results of other studies showing that ezetimibe, either alone or in combination with statins, is less effective in improving endothelial function than statin monotherapy. 7, 8 Nevertheless, because of ethnic and other background differences that could affect differential responses to statin therapy, we agree that there is a need for a larger-scale and perhaps multicenter study to further investigate whether changes in endothelial function with statin therapy are solely dependent on LDL-C lowering.
The primary reason for measuring ROCK activity and FMD is that inhibition of ROCK by the ROCK inhibitor, fasudil, leads to improvement in FMD (without changes in LDL-C) in humans with atherosclerosis. 9 Because statins could inhibit ROCK, we were interested in determining whether ROCK inhibition correlated with LDL-C reduction and, if not, whether this constituted a "pleiotropic" effect of statin therapy. Furthermore, we recently found that a higher statin dose (atorvastatin 80 mg) inhibited ROCK activity more than a lower statin dose (atorvastatin 10 mg). 10 This finding forms the basis for the rationale of this study as we compared a higher dose of simvastatin with a lower dose of simvastatin and ezetimibe with equal LDL-C reduction. As pointed out by Tershakovec et al, lowering LDL-C (primarily with statin therapy) has consistently been shown to reduce cardiovascular risks. However, it is not clear whether the magnitude of benefits obtained by similar LDL-C lowering with nonstatin therapy is comparable to that of statin therapy. Perhaps it is not only the level of LDL-C achieved but also how you get there that is important for cardiovascular risk reduction. For example, in patients with normal or low LDL-C, statin therapy appears to confer greater cardiovascular risk reductions compared
